Table 1

Demographic parameter, diagnostic tests, diagnoses and treatment of 76 juvenile patients with RMD with laboratory-proven SARS-CoV-2 infection

PatientsTotal cohortSymptomaticAsymptomatic
Female, %525544
Age, median (IQR)14 (11–16.5)14 (12–17)12 (7–16)
Test method, n (%)
 PCR54 (71)41 (71)13 (72)
 Antigen test3 (4)3 (5)0 (0)
 Antibody test19 (25)14 (24)5 (28)
Juvenile idiopathic arthritis, n (%)44 (58)33 (57)11 (61)
 Oligoarthritis (persistent/extended)16115
 Polyarthritis (RF negative/positive)17152
 Enthesitis-related arthritis743
 Systemic juvenile idiopathic arthritis330
 Other arthritis101
Autoinflammatory diseases, n (%)18 (24)18 (31)0
 NLRP3-associated autoinflammatory disease220
Connective tissue disease, n (%)6 (8)3 (5)3 (17)
 Sjögren’s syndrome111
 Scleroderma (localised)101
Other, n (%)8 (11)4 (7)4 (22)
 Behçet's disease110
 Sjögren‘s syndrome110
 Uveitis (idiopathic)202
Treatment, n (%)66 (87)49 (84)17 (94)
 Systemic glucocorticoids844
 Any DMARD58499
 TNF-α antagonist19172
 MTX+TNF-α antagonist440
 IL-6 blockade651
 IL-1 blockade440
 Mycophenolate mofetil321
  • (b)DMARD, (biological) disease-modifying antirheumatic drug; CRMO, chronic recurrent multifocal osteomyelitis; DADA2, deficiency of adenosine deaminase 2; FMF, familial Mediterranean fever ; IL, interleukin; JDM, juvenile dermatomyositis; MTX, methotrexate; PFAPA, periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; SpA, spondylarthritis, the patient was older than 16 years at the time of diagnosis and therefore could not be classified as having enthesitis-related arthritis; TNF, tumour necrosis factor; TRAPS, TNF-receptor-associated periodic syndrome.